CAPR Capricor Therapeutics, Inc.

0.83
+0.04  (5%)
Previous Close 0.79
Open 0.75
Price To book 0.00
Market Cap 17.76M
Shares 21,399,000
Volume 257,957
Short Ratio 1.56
Av. Daily Volume 191,900

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 completed. Waiting on data from additional study to determine future
Cenderitide
Ambulatory heart failure
Phase 1/2 data released April 25, 2017. Noted improvement in certain measures of cardiac and upper limb function. 12-month data due 4Q 2017.
CAP-1002 HOPE-Duchenne
Duchenne Muscular Dystrophy (DMD)
Phase 2 data released May 12, 2017 - primary endpoint unlikely to be met.
CAP-1002 ALLSTAR
Myocardial infarction (heart attack)

Latest News

  1. Capricor Therapeutics Announces Formation of Duchenne Muscular Dystrophy Advisory Board
  2. Capricor reports 1Q loss
  3. Capricor Therapeutics Reports First Quarter 2017 Financial Results and Provides Corporate Update
  4. Investor Network: Capricor Therapeutics, Inc. to Host Earnings Call
  5. Capricor Therapeutics Provides Update on ALLSTAR Trial
  6. Capricor Therapeutics Announces Private Placement of Common Stock
  7. Capricor Therapeutics to Hold First Quarter 2017 Financial Results and Corporate Update Conference Call on Monday, May 15
  8. Blog Coverage Capricor Announces Positive Results from Trial for the Treatment of Duchenne Muscular Dystrophy
  9. Capricor Therapeutics to Present at the Alliance for Regenerative Medicine's Cell & Gene Therapy Investor Day
  10. ETFs with exposure to Capricor Therapeutics, Inc. : April 25, 2017
  11. Capricor Therapeutics Stock Surging on Positive Muscular Dystrophy Trial Results
  12. Capricor Therapeutics Announces Positive Six-Month Results from the Randomized Phase I/II HOPE Clinical Trial in Duchenne Muscular Dystrophy
  13. Capricor Therapeutics to Report Six-Month Results from the Randomized Phase I/II HOPE Clinical Trial in Duchenne Muscular Dystrophy
  14. Rockwell Medical (RMTI) Looks Good: Stock Moves 5.9% Higher
  15. Capricor Therapeutics, Inc. :CAPR-US: Earnings Analysis: Q4, 2016 By the Numbers : March 21, 2017
  16. Capricor Therapeutics Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Corporate Update
  17. Investor Network Invites You to the Capricor Therapeutics Fourth Quarter and Full Year 2016 Business Update and Financial Results Conference Call and Webcast on Wednesday, March 15, 2017
  18. Capricor Therapeutics to Hold Fourth Quarter and Full Year 2016 Financial Results and Corporate Update Conference Call on Wednesday, March 15

SEC Filings

  1. D - Notice of Exempt Offering of Securities 17856168
  2. 10-Q - Quarterly report [Sections 13 or 15(d)] 17845448
  3. 8-K - Current report 17844477
  4. 8-K - Current report 17836361
  5. SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals 17836165
  6. 8-K/A [Amend] - Current report 17826070
  7. 8-K - Current report 17820620
  8. 8-K - Current report 17781735
  9. 8-K - Current report 17779615
  10. DEF 14A - Other definitive proxy statements 17774153